Eton Pharmaceuticals (ETON) Price & Analysis

Compare

525 Followers

ETON Stock Chart & Stats

$15.39

-$0.03(-0.25%)

At close: Jan 08 4:00 PM EST

$15.39

-$0.03(-0.25%)

Day’s Range― - ―

52-Week Range$11.09 - $23.00

Previous CloseN/A

Volume127.06K

Average Volume (3M)183.70K

Market Cap

$406.82M

Enterprise Value$378.86M

Total Cash (Recent Filing)$37.12M

Total Debt (Recent Filing)$3.26M

Price to Earnings (P/E)―

Beta1.11

Next Earnings

Mar 12, 2026

EPS Estimate

0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.04

Shares Outstanding26,817,535

10 Day Avg. Volume158,799

30 Day Avg. Volume183,699

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)14.12

Price to Sales (P/S)8.84

P/FCF Ratio365.77

Enterprise Value/Market Cap0.93

Enterprise Value/Revenue5.39

Enterprise Value/Gross Profit10.49

Enterprise Value/Ebitda286.36

Forecast

1Y Price Target

$30.50

Price Target Upside98.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical PipelineFive clinical candidates in development could translate into meaningful new product sales if approved, creating a clear pathway to expand future revenue beyond the current portfolio.

Commercial ExecutionManagement projects label expansions for Khindivi and Increlex, together with a strong Increlex relaunch, could materially increase peak product sales and support higher revenue growth.

Strategic Transactions And Regulatory CatalystsAn anticipated FDA decision on ET-600 combined with planned acquisition activity could add marketed products and broaden the commercial base, creating upside to earnings projections.

Bears Say

Eton Pharmaceuticals News

Eton licenses U.S. marketing rights to ultra-rare disease product candidate

Eton Pharmaceuticals (ETON) announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved,...

2d ago

ETON

Eton Pharmaceuticals Licenses U.S. Rights to Ultra-Rare Drug

Eton Pharmaceuticals ( ($ETON) ) just unveiled an update. On February 2, 2026, Eton Pharmaceuticals announced it had...

2d ago

ETON

Eton Pharmaceuticals: Promising Growth Trajectory with Projected Revenue Surge and Strategic Developments

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Eton Pharmaceuticals today and set a price target...

2M ago

ETON

Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference

The latest announcement is out from Eton Pharmaceuticals ( ($ETON) ). On December 4, 2025, Eton Pharmaceuticals, Inc....

2M ago

ETON

Eton Pharmaceuticals management to meet with B. Riley

Breakfast Meeting with Management in New York on December 3 hosted by B. Riley. Published first on TheFly...

2M ago

ETON

Eton Pharmaceuticals Reports Strong Q3 Growth Amid Challenges

Eton Pharmaceuticals (($ETON)) has held its Q3 earnings call. Read on for the main highlights of the call....

3M ago

ETON

Eton Pharmaceuticals: Promising Growth Trajectory with Strong Revenue Performance and Strategic Expansions Justifying Buy Rating

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Eton Pharmaceuticals, with...

3M ago

ETON

Eton Pharmaceuticals Reports Strong Q3 2025 Growth

Eton Pharmaceuticals ( ($ETON) ) has released its Q3 earnings. Here is a breakdown of the information Eton...

3M ago

ETON

Eton Pharmaceuticals management to meet virtually with Craig-Hallum

Virtual Meeting to be held on September 25 hosted by Craig-Hallum. Published first on TheFly – the ultimate...

5M ago

ETON

Eton Pharmaceuticals Reports Strong Q2 Growth Amid Challenges

Eton Pharmaceuticals (($ETON)) has held its Q2 earnings call. Read on for the main highlights of the call....

6M ago

ETON

Eton Pharmaceuticals Reports Robust Q2 2025 Growth

Eton Pharmaceuticals ( ($ETON) ) has released its Q2 earnings. Here is a breakdown of the information Eton...

6M ago

ETON

Eton Pharmaceuticals reports Q2 non-GAAP EPS 3c, consensus 2c

Reports Q2 revenue $18.9M, consensus $16.71M. “Eton continues to execute on all fronts. During the second quarter, we...

6M ago

ETON

Eton Pharmaceuticals sees reaching annual revenue run rate of $80M in Q3

16:37 EDT Eton Pharmaceuticals (ETON) sees reaching annual revenue run rate of $80M in Q3 Published first on...

6M ago

ETON

Eton Pharmaceuticals’ ET-600 Launch and Strategic Expansion Drive Buy Rating

H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on ETON stock, giving a Buy rating yesterday....

7M ago

ETON

ETON FAQ

What was Eton Pharmaceuticals Inc’s price range in the past 12 months?

Eton Pharmaceuticals Inc lowest stock price was $11.09 and its highest was $23.00 in the past 12 months.

What is Eton Pharmaceuticals Inc’s market cap?

Eton Pharmaceuticals Inc’s market cap is $406.82M.

When is Eton Pharmaceuticals Inc’s upcoming earnings report date?

Eton Pharmaceuticals Inc’s upcoming earnings report date is Mar 12, 2026 which is in 36 days.

How were Eton Pharmaceuticals Inc’s earnings last quarter?

Eton Pharmaceuticals Inc released its earnings results on Nov 06, 2025. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.09 by -$0.05.

Is Eton Pharmaceuticals Inc overvalued?

According to Wall Street analysts Eton Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eton Pharmaceuticals Inc pay dividends?

Eton Pharmaceuticals Inc does not currently pay dividends.

What is Eton Pharmaceuticals Inc’s EPS estimate?

Eton Pharmaceuticals Inc’s EPS estimate is 0.13.

How many shares outstanding does Eton Pharmaceuticals Inc have?

Eton Pharmaceuticals Inc has 26,817,535 shares outstanding.

What happened to Eton Pharmaceuticals Inc’s price movement after its last earnings report?

Eton Pharmaceuticals Inc reported an EPS of $0.04 in its last earnings report, missing expectations of $0.09. Following the earnings report the stock price went down -11.703%.

Which hedge fund is a major shareholder of Eton Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in ETON

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Eton Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.17%

Trailing 12-Months

Asset Growth

191.59%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eton Pharmaceuticals (ETON) Earnings & Revenues

Historic Earnings Reports

ETON Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Eton Pharmaceuticals experienced substantial revenue growth and strong performance from key products, leading to positive cash flow generation and profitability. However, the company faced challenges with net income, patient count for INCRELEX, and FDA restrictions on KHINDIVI. Despite these challenges, the overall outlook remains positive with strategic initiatives underway.View all ETON earnings summaries

ETON Stock 12 Month Forecast

Average Price Target

$30.50

▲(98.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","36":"$36","17.25":"$17.25","23.5":"$23.5","29.75":"$29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,17.25,23.5,29.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.17,16.695384615384615,18.220769230769232,19.746153846153845,21.271538461538462,22.796923076923076,24.322307692307692,25.847692307692306,27.373076923076923,28.89846153846154,30.423846153846153,31.949230769230766,33.47461538461538,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.17,16.34923076923077,17.52846153846154,18.70769230769231,19.886923076923075,21.066153846153846,22.245384615384616,23.424615384615386,24.603846153846156,25.783076923076926,26.962307692307693,28.14153846153846,29.32076923076923,{"y":30.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.17,16.00307692307692,16.836153846153845,17.66923076923077,18.502307692307692,19.335384615384616,20.16846153846154,21.00153846153846,21.834615384615383,22.667692307692306,23.50076923076923,24.333846153846153,25.166923076923077,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.91,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.17,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >